1. Home
  2. GSBD vs CLDX Comparison

GSBD vs CLDX Comparison

Compare GSBD & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSBD
  • CLDX
  • Stock Information
  • Founded
  • GSBD 2012
  • CLDX N/A
  • Country
  • GSBD United States
  • CLDX United States
  • Employees
  • GSBD N/A
  • CLDX N/A
  • Industry
  • GSBD Finance: Consumer Services
  • CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • GSBD Finance
  • CLDX Health Care
  • Exchange
  • GSBD Nasdaq
  • CLDX Nasdaq
  • Market Cap
  • GSBD 1.4B
  • CLDX 1.3B
  • IPO Year
  • GSBD N/A
  • CLDX 2008
  • Fundamental
  • Price
  • GSBD $11.55
  • CLDX $20.50
  • Analyst Decision
  • GSBD Sell
  • CLDX Buy
  • Analyst Count
  • GSBD 2
  • CLDX 9
  • Target Price
  • GSBD $12.00
  • CLDX $50.00
  • AVG Volume (30 Days)
  • GSBD 516.9K
  • CLDX 1.2M
  • Earning Date
  • GSBD 08-07-2025
  • CLDX 08-07-2025
  • Dividend Yield
  • GSBD 16.50%
  • CLDX N/A
  • EPS Growth
  • GSBD N/A
  • CLDX N/A
  • EPS
  • GSBD 0.45
  • CLDX N/A
  • Revenue
  • GSBD $419,771,000.00
  • CLDX $7,559,000.00
  • Revenue This Year
  • GSBD N/A
  • CLDX N/A
  • Revenue Next Year
  • GSBD N/A
  • CLDX N/A
  • P/E Ratio
  • GSBD $25.94
  • CLDX N/A
  • Revenue Growth
  • GSBD N/A
  • CLDX 24.49
  • 52 Week Low
  • GSBD $9.51
  • CLDX $14.40
  • 52 Week High
  • GSBD $15.81
  • CLDX $47.00
  • Technical
  • Relative Strength Index (RSI)
  • GSBD 59.85
  • CLDX 52.11
  • Support Level
  • GSBD $11.25
  • CLDX $19.77
  • Resistance Level
  • GSBD $11.56
  • CLDX $24.03
  • Average True Range (ATR)
  • GSBD 0.16
  • CLDX 1.31
  • MACD
  • GSBD -0.00
  • CLDX -0.00
  • Stochastic Oscillator
  • GSBD 67.92
  • CLDX 26.15

About GSBD Goldman Sachs BDC Inc.

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company's origination strategy focuses on leading the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

About CLDX Celldex Therapeutics Inc.

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Share on Social Networks: